Gender diversity is not where it should be at Novo Nordisk, even though the pharmaceutical giant has launched a series of diversity initiatives from the viewpoint of the firm's Chairman of the Board Helge Lund, according to newspaper Børsen.
"For many years I took for granted that women and men had equal opportunities, and I was pretty relaxed about gender, but looking back, I was probably too relaxed, and over the years I have discovered that as a leader I have not done enough," Lund stated on a Thursday video connection at an annual board summit organized by the Danish Chamber of Commerce (Dansk Erhverv, -ed.), Axcel Future and the Board Leadership Society (bestyrelsesforeningen, -ed.)
More from MedWatch
In 2015, Genmab partnered with relatively unknown biotech firm Biontech. Reflecting on how far Genmab has come since, CEO Jan van de Winkel is still confident that partnerships, rather than acquisitions, are the way forward. If it had acquired Biontech at the time, the CEO speculates Genmab may have put a stop to other activities – including the Covid-19 vaccine efforts that went on to save millions of lives. This and fairness are worth remembering as biotech firms are increasingly strapped for cash, van de Winkel reflects.